Biotech Preview: Genzyme, Biogen, Amgen, Celgene

Despite regulatory hold-ups, reimbursement and labeling issues, some troubled drug sales and a company sale that never happened in 2007, a few big biotech stocks maintain bullish outlooks for fourth-quarter and year-end results, as well as the year ahead.

Genzyme(GENZ), Biogen Idec(BIIB), Amgen(AMGN) and Celgene(CELG) each preannounced fourth-quarter and annual results in conjunction with last week's JPMorgan Healthcare Conference in San Francisco. They guided ahead optimistically. Meanwhile, Genentech(DNA) will share its numbers post-close today and Gilead(GILD) will announce later in January.

Here's a look at what investors saw and expect to see from these companies.

Genentech -- Jan. 14

...